JaLCDOI 10.18926/AMO/55661
フルテキストURL 72_1_39.pdf
著者 Hosogi, Mika| Morizane, Yuki| Shiode, Yusuke| Doi, Shinichiro| Kumase, Fumiaki| Kimura, Shuhei| Hosokawa, Mio| Hirano, Masayuki| Toshima, Shinji| Takahashi, Kosuke| Fujiwara, Atsushi| Shiraga, Fumio|
抄録 To investigate the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). We retrospectively examined 35 eyes of 35 patients with ME due to BRVO who underwent TAE for 1 year. Patients whose treatment interval extended to 12 weeks were switched to a pro re nata regimen (PRN; TAE to PRN group), while TAE was continued for patients whose treatment interval was less than 12 weeks (continued TAE group). Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and predictive factors for inclusion in the TAE to PRN group were analyzed. BCVA and CRT both improved significantly at 1 year compared with baseline (p<0.001). Sixteen eyes (45.7%) were included in the TAE to PRN group, while 19 eyes (54.3%) were included in the continued TAE group. BCVA in the TAE to PRN group was significantly better than that in the continued TAE group at 1 year (p=0.047). BCVA at baseline and macular BRVO were significant predictive factors for inclusion in the TAE to PRN group. TAE was effective for improving BCVA and CRT. The TAE to PRN group showed significantly better prognosis.
キーワード branch retinal vein occlusion macular edema anti-vascular endothelial growth factor ranibizumab treat-and-extend regimen
Amo Type Original Article
発行日 2018-02
出版物タイトル Acta Medica Okayama
出版者 Okayama University Medical School
開始ページ 39
終了ページ 45
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 29463937
Web of Sience KeyUT 000426542800006
NAID 120006398861